

1 ZACHARY A. KELLER (Texas 24087838)
zkeller@ftc.gov; (214) 979-9382
2 REID A. TEPFER (Texas 24079444)
rtepfer@ftc.gov; (214) 979-9395
3 EDWARD HYNES (New York 4887584)
ehynes@ftc.gov; (214) 979-9381
4 Federal Trade Commission
5 1999 Bryan Street, Suite 2150
6 Dallas, Texas 75201
7 Fax: (214) 953-3079

8 **UNITED STATES DISTRICT COURT**
9 **EASTERN DISTRICT OF CALIFORNIA**

10
11 **FEDERAL TRADE COMMISSION,**
12
13 Plaintiff,
14
15 vs.
16 **GOLDEN SUNRISE NUTRACEUTICAL,**
INC., et al.,
17
18 Defendants.

Case No.: 1:20-cv-01060-DAD-SKO

**STIPULATED ORDER FOR
PERMANENT INJUNCTION AND
MONETARY JUDGMENT AS TO
DEFENDANT STEPHEN MEIS**

19 Plaintiff, the Federal Trade Commission (“Commission” or “FTC”), filed its Complaint
20 For Permanent Injunction and Other Equitable Relief (“Complaint”), pursuant to Section 13(b)
21 of the Federal Trade Commission Act (“FTC Act”), 15 U.S.C. § 53(b), (Doc. No. 2.) The
22 Commission and Defendant Stephen Meis (“Meis”) stipulate to the entry of this Stipulated Order
23 for Permanent Injunction and Monetary Judgment (“Order”) to resolve all matters in dispute in
24 this action between them, including potential action by Plaintiff under Section 19(a)(2) of the
25 FTC Act, 15 U.S.C § 57b(a)(2).

26 THEREFORE, IT IS ORDERED as follows:

27
28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT
AS TO STEPHEN MEIS- PAGE 1**

FINDINGS

1
2 1. This Court has jurisdiction over this matter.

3 2. The Complaint charges that Defendants participated in deceptive acts or practices
4 in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, in connection
5 with the labeling, advertising, marketing, distribution, and sale of products they claim will treat,
6 prevent, or cure COVID-19, cancer, and Parkinson’s disease.
7

8 3. Defendant Meis neither admits nor denies any of the allegations in the Complaint,
9 except as specifically stated in this Order. Only for purposes of this action, Defendant Meis
10 admits the facts necessary to establish jurisdiction.
11

12 4. Defendant Meis waives any claim that he may have under the Equal Access to
13 Justice Act, 28 U.S.C. § 2412, concerning the prosecution of this action through the date of this
14 Order, and agree to bear his own costs and attorney fees.

15 5. Defendant Meis and the Commission waive all rights to appeal or otherwise
16 challenge or contest the validity of this Order.
17

DEFINITIONS

18 For purposes of this Order, the following definitions apply:

19 A. **“Covered Product”** means any Dietary Supplement, Food, or Drug, including
20 the products Defendants have marketed as ImunStem, Aktiffvate, AnterFerron-1, AnterFerron-2,
21 CrProtein, DetoxHerb-1, DetoxHerb-2, DetoxHerb-NR, DetoxHerb-PI, KemoHerb-1,
22 KemoHerb-2, KemoHerb-NR, KemoHerb-PI, HyProtein-1, HyProtein-2, HyProtein-3,
23 HyProtein-4, and LyProtein.
24

25 B. **“Defendants”** means all of the Corporate Defendants and Individual Defendants,
26
27

1 individually, collectively, or in any combination.

2 1. “**Corporate Defendants**” means Golden Sunrise Nutraceutical, Inc. and Golden
3 Sunrise Pharmaceutical, Inc., and their successors and assigns.

4 2. “**Individual Defendants**” means Huu Tieu and Stephen Meis.

5
6 C. “**Dietary Supplement**” means: (1) any product labeled as a dietary supplement or
7 otherwise represented as a dietary supplement; or (2) any pill, tablet, capsule, powder, softgel,
8 gelcap, liquid, or other similar form containing one or more ingredients that are a vitamin,
9 mineral, herb or other botanical, amino acid, probiotic, or other dietary substance for use by
10 humans to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite,
11 constituent, extract, or combination of any ingredient described above, that is intended to be
12 ingested, and is not represented to be used as a conventional food or as a sole item of a meal or
13 the diet.
14

15 D. “**Drug**” means: (1) articles recognized in the official United States
16 Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National
17 Formulary, or any supplement to any of them; (2) articles intended for use in the diagnosis, cure,
18 mitigation, treatment, or prevention of disease in humans or other animals; (3) articles (other
19 than Food) intended to affect the structure or any function of the body of humans or other
20 animals; and (4) articles intended for use as a component of any article specified in (1), (2), or
21 (3); but does not include devices or their components, parts, or accessories.
22
23

24 E. “**Essentially Equivalent Product**” means a product that contains the identical
25 ingredients, except for inactive ingredients (e.g., inactive binders, colors, fillers, excipients), in
26 the same form and dosage, and with the same route of administration (e.g., orally, sublingually),
27

1 as the Covered Product; provided that the Covered Product may contain additional ingredients if
2 reliable scientific evidence generally accepted by experts in the field indicates that the amount
3 and combination of additional ingredients are unlikely to impede or inhibit the effectiveness of
4 the ingredients in the Essentially Equivalent Product.
5

6 F. “**FDA**” means the United States Food and Drug Administration.

7 G. “**Food**” means: (1) any article used for food or drink for humans or other animals;
8 (2) chewing gum; and (3) any article used for components of any such article.
9

10 **ORDER**

11 **I. PROHIBITED REPRESENTATIONS REGARDING HEALTH-RELATED 12 CLAIMS REQUIRING HUMAN CLINICAL TESTING FOR SUBSTANTIATION**

13 **IT IS ORDERED** that Defendant Meis and his officers, agents, employees, and
14 attorneys, and all other persons in active concert or participation with any of them, who receive
15 actual notice of this Order, whether acting directly or indirectly, in connection with the
16 manufacturing, labeling, advertising, promotion, offering for sale, or sale of any Covered
17 Product are permanently restrained and enjoined from making, or assisting others in making,
18 expressly or by implication, any representation that such product:
19

20 (1) treats, mitigates the symptoms of, or cures COVID-19;

21 (2) treats, mitigates the symptoms of, or cures cancer;

22 (3) treats, mitigates the symptoms of, or cures Parkinson’s disease; or

23 (4) prevents, treats, mitigates the symptoms of, or cures any disease, unless the
24 representation is non-misleading, and, at the time of making such representation, they possess
25 and rely upon competent and reliable scientific evidence substantiating that the representation is
26 true.
27

28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT
AS TO STEPHEN MEIS- PAGE 4**

1 For purposes of this Section, “competent and reliable scientific evidence” must consist of
2 human clinical testing of the Covered Product, or of an Essentially Equivalent Product, that is
3 sufficient in quality and quantity, based on standards generally accepted by experts in the
4 relevant disease, condition, or function to which the representation relates, when considered in
5 light of the entire body of relevant and reliable scientific evidence, to substantiate that the
6 representation is true. Such testing must be: (1) randomized, double-blind, and placebo-
7 controlled; and (2) conducted by researchers qualified by training and experience to conduct
8 such testing. In addition, all underlying or supporting data and documents generally accepted by
9 experts in the field as relevant to an assessment of such testing as described in the Section titled
10 “Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies”
11 must be available for inspection and production to the Commission. Persons covered by this
12 Section have the burden of proving that a product satisfies the definition of an Essentially
13 Equivalent Product.
14
15

16 **II. PROHIBITED REPRESENTATIONS: OTHER HEALTH-RELATED CLAIMS**

17 **IT IS FURTHER ORDERED** that Defendant Meis and his officers, agents, employees,
18 and attorneys, and all other persons in active concert or participation with any of them, who
19 receive actual notice of this Order, whether acting directly or indirectly, in connection with the
20 manufacturing, labeling, advertising, promotion, offering for sale, or sale of any Covered
21 Product are permanently restrained and enjoined from making, or assisting others in making,
22 expressly or by implication, any representation other than representations covered under the
23 Section of this Order entitled “Prohibited Representations Regarding Health-Related Claims
24 Requiring Human Clinical Testing For Substantiation” about the health benefits, performance,
25
26
27

1 efficacy, safety, or side effects of any Covered Product, unless the representation is non-
2 misleading, and, at the time of making such representation, they possess and rely upon
3 competent and reliable scientific evidence that is sufficient in quality and quantity based on
4 standards generally accepted by experts in the disease, condition, or function to which the
5 representation relates, when considered in light of the entire body of relevant and reliable
6 scientific evidence, to substantiate that the representation is true.

8 For purposes of this Section, “competent and reliable scientific evidence” means tests,
9 analyses, research, or studies (1) that have been conducted and evaluated in an objective manner
10 by experts in the relevant disease, condition, or function to which the representation relates; (2)
11 that are generally accepted by such experts to yield accurate and reliable results; and (3) that are
12 randomized, double-blind, and placebo-controlled human clinical testing of the Covered Product,
13 or of an Essentially Equivalent Product, when such experts would generally require such human
14 clinical testing to substantiate that the representation is true. In addition, when such tests or
15 studies are human clinical tests or studies, all underlying or supporting data and documents
16 generally accepted by experts in the field as relevant to an assessment of such testing as set forth
17 in the Section entitled “Preservation of Records Relating to Competent and Reliable Human
18 Clinical Tests or Studies” must be available for inspection and production to the Commission.
19 Persons covered by this Section have the burden of proving that a product satisfies the definition
20 of an Essentially Equivalent Product.
21
22

24 **III. PRESERVATION OF RECORDS RELATING TO COMPETENT AND**
25 **RELIABLE HUMAN CLINICAL TESTS OR STUDIES**

26 **IT IS FURTHER ORDERED** that, with regard to any human clinical test or study
27 (“Test”) upon which Defendant Meis relies to substantiate any claim covered by this Order,

28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT**
AS TO STEPHEN MEIS- PAGE 6

1 Defendant Meis must secure and preserve all underlying or supporting data and documents
2 generally accepted by experts in the field as relevant to an assessment of the Test, including:

3 A. All protocols and protocol amendments, reports, articles, write-ups, or other
4 accounts of the results of the Test, and drafts of such documents reviewed by the Test sponsor or
5 any other person not employed by the research entity;

6 B. All documents referring or relating to recruitment; randomization; instructions,
7 including oral instructions, to participants; and participant compliance;

8 C. Documents sufficient to identify all Test participants, including any participants
9 who did not complete the Test, and all communications with any participants relating to the Test;
10 all raw data collected from participants enrolled in the Test, including any participants who did
11 not complete the Test; source documents for such data; any data dictionaries; and any case report
12 forms;
13

14 D. All documents referring or relating to any statistical analysis of any Test data,
15 including any pretest analysis, intent-to-treat analysis, or between-group analysis performed on
16 any Test data; and
17

18 E. All documents referring or relating to the sponsorship of the Test, including all
19 communications and contracts between any sponsor and the Test's researchers.
20

21 *Provided, however,* the preceding preservation requirement does not apply to a Reliably
22 Reported Test, unless the Test was conducted, controlled, or sponsored, in whole or in part by:
23 (1) any Defendant; (2) any Defendant's officers, agents, representatives, or employees; (3) any
24 other person or entity in active concert or participation with any Defendant; (4) any person or
25 entity affiliated with or acting on behalf of any Defendant; (5) any supplier of any ingredient
26
27

1 contained in the product at issue to any of the foregoing or to the product's manufacturer; or (6)
2 the supplier or manufacturer of such product.

3 For purposes of this Section, "Reliably Reported Test" means a report of the Test has
4 been published in a peer-reviewed journal, and such published report provides sufficient
5 information about the Test for experts in the relevant field to assess the reliability of the results.
6

7 For any Test conducted, controlled, or sponsored, in whole or in part, by Defendant Meis,
8 Defendant Meis must establish and maintain reasonable procedures to protect the confidentiality,
9 security, and integrity of any personal information collected from or about participants. These
10 procedures must be documented in writing and must contain administrative, technical, and
11 physical safeguards appropriate to the size, complexity, nature, and scope of Defendant Meis's
12 activities, and the sensitivity of the personal information collected from or about the participants.
13

14 **IV. PROHIBITED MISREPRESENTATIONS REGARDING TESTS, STUDIES,**
15 **OTHER RESEARCH, OR FDA APPROVAL**

16 **IT IS FURTHER ORDERED** that Defendant Meis and his officers, agents, employees,
17 and attorneys, and all other persons in active concert or participation with any of them, who
18 receive actual notice of this Order, whether acting directly or indirectly, in connection with the
19 manufacturing, labeling, advertising, promotion, offering for sale, or sale of any product are
20 permanently restrained and enjoined from misrepresenting, in any manner, expressly or by
21 implication:
22

23 A. That any Covered Product is:

24 (i) clinically proven to treat, mitigate the symptoms of, or cure COVID-19;

25 (ii) clinically proven to treat, mitigate the symptoms of, or cure cancer;

26 (iii) clinically proven to treat, mitigate the symptoms of, or cure Parkinson's
27

28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT**
AS TO STEPHEN MEIS- PAGE 8

1 disease;

2 (iv) clinically proven to prevent, treat, mitigate the symptoms of, or cure any
3 disease or condition;

4 (v) accepted, approved, authorized, endorsed, or proven effective by the FDA; or

5 (vi) accepted, approved, authorized, or registered by the FDA as a Dietary
6 Supplement, Drug, or Regenerative Medicine Advance Therapy;

7
8 B. That the performance or benefits of any product are scientifically or clinically
9 proven or otherwise established; or

10 C. The existence, contents, validity, results, conclusions, or interpretations of any
11 Test, study, or other research.

12
13 **V. FDA APPROVED CLAIMS**

14 **IT IS FURTHER ORDERED** that nothing in this Order prohibits Defendant Meis or his
15 officers, agents, employees, and attorneys, or all other persons in active concert or participation
16 with any of them, from:

17 A. For any Drug, making a representation that is approved in labeling for such Drug
18 under any tentative final or final monograph promulgated by the FDA, or under any new Drug
19 application approved by the FDA; and

20 B. For any product, making a representation that is specifically authorized in labeling
21 for such product by regulations promulgated by the FDA pursuant to the Nutrition Labeling and
22 Education Act of 1990 or authorized under Sections 303-304 of the Food and Drug
23 Administration Modernization Act of 1997.
24
25
26
27

1 his undersigned counsel holds in escrow for no purpose other than payment to the Commission.
2 Such payment must be made within 7 days of entry of this Order by electronic fund transfer in
3 accordance with instructions to be provided by a representative of the Commission.
4

5 **VIII. ADDITIONAL MONETARY PROVISIONS**

6 **IT IS FURTHER ORDERED** that:

7 A. Defendant Meis relinquishes dominion and all legal and equitable right, title, and
8 interest in all assets transferred pursuant to this Order and may not seek the return of any assets.

9 B. The facts alleged in the Complaint will be taken as true, without further proof, in
10 any subsequent civil litigation by or on behalf of the Commission, including in a proceeding to
11 enforce its rights to any payment or monetary judgment pursuant to this Order, such as a
12 nondischargeability complaint in any bankruptcy case.

13 C. The facts alleged in the Complaint establish all elements necessary to sustain an
14 action by the Commission pursuant to Section 523(a)(2)(A) of the Bankruptcy Code, 11 U.S.C.
15 § 523(a)(2)(A), and this Order will have collateral estoppel effect for such purposes.
16

17 D. Defendant Meis acknowledges that his Taxpayer Identification Numbers (Social
18 Security Numbers or Employer Identification Numbers), which Defendant Meis previously
19 submitted to the Commission, may be used for collecting and reporting on any delinquent
20 amount arising out of this Order, in accordance with 31 U.S.C. §7701.
21

22 E. All money paid to the Commission pursuant to this Order may be deposited into a
23 fund administered by the Commission or its designee to be used for consumer redress and any
24 attendant expenses for the administration of any redress fund. If a representative of the
25 Commission decides that direct redress to consumers is wholly or partially impracticable or
26
27

28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT
AS TO STEPHEN MEIS- PAGE 11**

1 money remains after redress is completed, the Commission may apply any remaining money for
2 such other relief (including consumer information remedies) as it determines to be reasonably
3 related to Defendant's practices alleged in the Complaint. Any money not used for such
4 equitable relief is to be deposited to the U.S. Treasury as disgorgement. Defendant has no right
5 to challenge any actions the Commission or its representatives may take pursuant to this
6 Subsection.
7

8 **IX. NOTICE TO CUSTOMERS**

9 **IT IS FURTHER ORDERED** that Defendant Meis:
10

11 A. Identify all consumers who were prescribed or sold a Covered Product on or after
12 December 2016 ("Eligible Customers"):

- 13 1. Such Eligible Customers, and their contact information, must be identified to
14 the extent such information is in Defendant Meis's possession, custody, or
15 control, including from third parties.
16
17 2. Eligible Customers include those identified at any time up to one year after
18 the issuance of this Order.

19 B. Send each Eligible Customer a notice via electronic mail or, if electronic mailing
20 information is not available, by physical mail:

- 21
22 1. The notice must be in the form shown in **Attachment A**.
23
24 2. The envelope containing any notice sent by physical mail must be in the form
25 shown in **Attachment B**.
26
27 3. The subject line of the notice must state, "About Your Treatment With Golden
28 Sunrise Products."

1 4. The notice must not include any other attachments.

2 C. Notify all Eligible Customers within 45 days after the issuance date of this Order
3 and any Eligible Customers identified thereafter within 30 days of their identification.

4 D. Report on his notification program under penalty of perjury:

5 1. Defendant Meis must submit a report within 90 days after the issuance date of
6 this Order summarizing his compliance to date, including the total number of
7 Eligible Customers identified and notified.

8 2. If a representative of the Commission requests any information regarding the
9 program, including any of the underlying customer data, he must submit it
10 within 10 days of the request.

11 3. Failure to provide required notices or any requested information will be
12 treated as a continuing failure to obey this Order.

13 **X. NOTICE TO RESELLERS**

14 **IT IS FURTHER ORDERED** that within 30 days of the effective date of this Order,
15 Defendant Meis must notify all retailers or resellers by sending each by first-class mail, postage
16 paid and return receipt requested, or by courier service with signature proof of delivery, the
17 notification letter attached as **Attachment C**. Defendant Meis must include a copy of this Order,
18 but no other document or enclosure.

19 **XI. CUSTOMER INFORMATION**

20 **IT IS FURTHER ORDERED** that Defendant Meis and his officers, agents, employees,
21 and attorneys, and all other persons in active concert or participation with any of them, who
22

1 with the transactions or the occurrences that are the subject of the Complaint. Defendant Meis
2 must provide truthful and complete information, evidence, and testimony. Defendant Meis must
3 appear for interviews, discovery, hearings, trials, and any other proceedings that a Commission
4 representative may reasonably request upon 10 days written notice, or other reasonable notice, at
5 such places and times as a Commission representative may designate, without the service of a
6 subpoena.
7

8 **XIII. ORDER ACKNOWLEDGMENTS**

9 **IT IS FURTHER ORDERED** that Defendant Meis obtain acknowledgments of receipt
10 of this Order:
11

12 A. Defendant Meis, within 7 days of entry of this Order, must submit to the
13 Commission an acknowledgment of receipt of this Order sworn under penalty of perjury.

14 B. For 5 years after entry of this Order, Defendant Meis, for any business that such
15 Defendant, individually or collectively with any other Defendant, is the majority owner or
16 controls directly or indirectly, must deliver a copy of this Order to: (1) all principals, officers,
17 directors, and LLC managers and members; (2) all employees having managerial responsibilities
18 for conduct related to the subject matter of the Order and all agents and representatives who
19 participate in conduct related to the subject matter of the Order; and (3) any business entity
20 resulting from any change in structure as set forth in the Section titled Compliance Reporting.
21 Delivery must occur within 7 days of entry of this Order for current personnel. For all others,
22 delivery must occur before they assume their responsibilities.
23
24
25
26
27

1 C. From each individual or entity to which Defendant Meis delivered a copy of this
2 Order, Defendant Meis must obtain, within 30 days, a signed and dated acknowledgment of
3 receipt of this Order.
4

5 **XIV. COMPLIANCE REPORTING**

6 **IT IS FURTHER ORDERED** that Defendant Meis make timely submissions to the
7 Commission:

8 A. One year after entry of this Order, Defendant Meis must submit a compliance
9 report, sworn under penalty of perjury:

- 10
- 11 1. Defendant Meis must: (a) identify the primary physical, postal, and email address
12 and telephone number, as designated points of contact, which representatives of
13 the Commission may use to communicate with Defendant; (b) identify all of that
14 Defendant's businesses by all of their names, telephone numbers, and physical,
15 postal, email, and Internet addresses; (c) describe the activities of each business,
16 including the goods and services offered, the means of advertising, marketing, and
17 sales, and the involvement of any other Defendant (which Individual Defendants
18 must describe if they know or should know due to their own involvement); (d)
19 describe in detail whether and how that Defendant is in compliance with each
20 Section of this Order; and (e) provide a copy of each Order Acknowledgment
21 obtained pursuant to this Order, unless previously submitted to the Commission.
22
 - 23 2. Additionally, Defendant Meis must: (a) identify all telephone numbers and all
24 physical, postal, email and Internet addresses, including all residences; (b)
25 identify all business activities, including any business for which such Defendant
26
27

28 **STIPULATED PERMANENT INJUNCTION AND MONETARY JUDGMENT**
AS TO STEPHEN MEIS- PAGE 16

1 performs services whether as an employee or otherwise and any entity in which
2 such Defendant has any ownership interest; and (c) describe in detail such
3 Defendant's involvement in each such business, including title, role,
4 responsibilities, participation, authority, control, and any ownership.
5

6 B. For 7 years after entry of this Order, Defendant Meis must submit a compliance
7 notice, sworn under penalty of perjury, within 14 days of any change in the following:

- 8
- 9 1. Defendant Meis must report any change in: (a) any designated point of contact; or
10 (b) the structure of any Corporate Defendant or any entity that Defendant Meis
11 has any ownership interest in or controls directly or indirectly that may affect
12 compliance obligations arising under this Order, including: creation, merger, sale,
13 or dissolution of the entity or any subsidiary, parent, or affiliate that engages in
14 any acts or practices subject to this Order.
 - 15 2. Additionally, Defendant Meis must report any change in: (a) name, including
16 aliases or fictitious name, or residence address; or (b) title or role in any business
17 activity, including any business for which such Defendant performs services
18 whether as an employee or otherwise and any entity in which such Defendant has
19 any ownership interest, and identify the name, physical address, and any Internet
20 address of the business or entity.
21

22

23 C. Defendant Meis must submit to the Commission notice of the filing of any
24 bankruptcy petition, insolvency proceeding, or similar proceeding by or against such Defendant
25 within 14 days of its filing.
26

1 D. Any submission to the Commission required by this Order to be sworn under
2 penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746, such as by
3 concluding: “I declare under penalty of perjury under the laws of the United States of America
4 that the foregoing is true and correct. Executed on: _____” and supplying the date, signatory’s
5 full name, title (if applicable), and signature.
6

7 E. Unless otherwise directed by a Commission representative in writing, all
8 submissions to the Commission pursuant to this Order must be emailed to DEbrief@ftc.gov or
9 sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement,
10 Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW,
11 Washington, DC 20580. The subject line must begin: *FTC v. Golden Sunrise Nutraceutical, Inc.,*
12 *et al.*, 1:20-cv-01060-DAD-SKO.
13

14 **XV. RECORDKEEPING**

15 **IT IS FURTHER ORDERED** that Defendant Meis must create certain records for 7
16 years after entry of the Order, and retain each such record for 5 years. Specifically, Defendant
17 Meis, for any business that such Defendant, individually or collectively with any other
18 Defendants, is a majority owner or controls directly or indirectly, must create and retain the
19 following records:
20

21 A. Accounting records showing the revenues from all goods or services sold;

22 B. Personnel records showing, for each person providing services, whether as an
23 employee or otherwise, that person’s: name; addresses; telephone numbers; job title or position;
24 dates of service; and (if applicable) the reason for termination;
25
26
27

1 C. Records of all consumer complaints and refund requests, whether received
2 directly or indirectly, such as through a third party, and any response;

3 D. All records necessary to demonstrate full compliance with each provision of this
4 Order, including all submissions to the Commission; and

5 E. A copy of each unique advertisement or other marketing material.
6

7 **XVI. COMPLIANCE MONITORING**

8 **IT IS FURTHER ORDERED** that, for the purpose of monitoring Defendant Meis's
9 compliance with this Order, and any failure to transfer any assets as required by this Order:

10 A. Within 14 days of receipt of a written request from a representative of the
11 Commission, Defendant Meis must: submit additional compliance reports or other requested
12 information, which must be sworn under penalty of perjury; appear for depositions; and produce
13 documents for inspection and copying. The Commission is also authorized to obtain discovery,
14 without further leave of court, using any of the procedures prescribed by Federal Rules of Civil
15 Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45, and 69.
16

17 B. For matters concerning this Order, the Commission is authorized to communicate
18 directly with Defendant Meis. Defendant Meis must permit representatives of the Commission to
19 interview any employee or other person affiliated with any Defendant who has agreed to such an
20 interview. The person interviewed may have counsel present.
21

22 C. The Commission may use all other lawful means, including posing, through its
23 representatives as consumers, suppliers, or other individuals or entities, to Defendant Meis or any
24 individual or entity affiliated with Defendant Meis, without the necessity of identification or
25
26
27

1 prior notice. Nothing in this Order limits the Commission's lawful use of compulsory process,
2 pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49 and 57b-1.


3 D. Upon written request from a representative of the Commission any consumer
4 reporting agency must furnish consumer reports concerning Defendant Meis pursuant to Section
5 604(1) of the Fair Credit Reporting Act, 15 U.S.C. §1681b(a)(1).
6

7 **XVII. RETENTION OF JURISDICTION**

8 **IT IS FURTHER ORDERED** that this Court retains jurisdiction of this matter for
9 purposes of construction, modification, and enforcement of this Order.
10

11
12 IT IS SO ORDERED.

13 Dated: June 11, 2021

14 
15 _____
16 UNITED STATES DISTRICT JUDGE
17
18
19
20
21
22
23
24
25
26
27

ATTACHMENT A

RE: About Your Treatment With Golden Sunrise Products

Dear [Name of Consumer]:

Our records show that you received the Emergency D-Virus Plan of Care, the Metabolic Plan of Care, or the Cancer Plan of Care.

The Federal Trade Commission (FTC), the nation's consumer protection agency, sued Dr. Stephen Meis for deceptively advertising certain products as effective ways to treat, cure, or lessen the symptoms of COVID-19, cancer, and Parkinson's disease.

Contrary to the advertising claims:

- There is no competent and reliable scientific proof that the Emergency D-Virus Plan of Care can treat, cure, or lessen the symptoms of COVID-19.
- There is no competent and reliable scientific proof that the Metabolic Plan of Care or Cancer Plan of Care can treat, cure, or lessen the symptoms of cancer.
- There is no competent and reliable scientific proof that the Metabolic Plan of Care can treat, cure, or lessen the symptoms of Parkinson's disease.
- None of the treatment plans were FDA approved, designated as Regenerative Medicine Advanced Therapies, or designated safe and effective by the FDA.

As part of a settlement with the FTC, I agreed to stop making these claims.

For more information about this lawsuit, visit <https://www.ftc.gov/enforcement/cases-proceedings/202-3146/golden-sunrise-nutraceutical-inc>. Learn how to spot and avoid false and unproven COVID-19 product claims at [ftc.gov/coronavirus](https://www.ftc.gov/coronavirus).

Sincerely,

Stephen Meis
Former Medical Director
Golden Sunrise Nutraceutical, Inc.

ATTACHMENT B

The envelope for the notification letter must be in the following form, with the underlined text completed as directed:

[Identify Respondent
Street Address
City, State, and Zip Code]

FORWARDING AND RETURN POSTAGE GUARANTEED ADDRESS CORRECTION
SERVICE REQUESTED

[Name and
mailing address of customer,
including zip code]

ATTACHMENT C

[Date]
[Addressee]

RE: Removal of Misleading Health Treatment Claims Made by Golden Sunrise Nutraceutical, Golden Sunrise Pharmaceutical, Huu Tieu, and Stephen Meis

Dear Golden Sunrise Retailer:

The Federal Trade Commission (FTC), the nation's consumer protection agency, sued Dr. Stephen Meis for deceptively advertising certain products as effective ways to treat, cure, or lessen the symptoms of COVID-19, cancer, and Parkinson's disease.

To settle the charges, I have agreed to:

- Stop making claims that the Emergency D-Virus Plan of Care can treat, cure, or lessen the symptoms of COVID-19.
- Stop making claims that the Metabolic Plan of Care or Cancer Plan of Care can treat, cure, or lessen the symptoms of cancer.
- Stop making claims that the Metabolic Plan of Care can treat, cure, or lessen the symptoms of Parkinson's disease.
- Stop making claims that the plans of care were FDA approved, designated as Regenerative Medicine Advanced Therapies, or designated safe and effective by the FDA.

You should remove any point-of-sale displays, posters, or other materials on display that include any of the deceptive claims.

You can find out more about the settlement at <https://www.ftc.gov/enforcement/cases-proceedings/202-3146/golden-sunrise-nutraceutical-inc>. Please contact me if you have any questions at [contact information].

I thank you for your business and greatly appreciate your cooperation in this matter.

Sincerely,

Stephen Meis
Former Medical Director
Golden Sunrise Nutraceutical, Inc.